Moreover, our data indicates that YCLLT-MS promoted the activation of the AdipoR1/AMPK/SIRT1 signaling pathway and may inhibit lipid deposition, inflammatory injury, and ameliorate mitochondrial dysfunction in the NAFLD cell model by regulating AdipoR1. This evidence concerns the gene SIRT1 and metabolic dysfunction-associated steatotic liver disease.